Summary — A.1248 (2025)
Title: Prohibits the sale of xylazine above a certain weight
Primary sponsor: Yudelka Tapia (with numerous cosponsors)
Introduced: January 9, 2025
Status (most recent): Recommitted to Consumer Protection (May 27, 2025)
Related/companion: S.7668; prior-session A.6506
Purpose / intent
The bill’s stated purpose (per the bill title) is to prohibit sale of xylazine in amounts greater than a specified weight. Xylazine is a veterinary sedative that has been increasingly detected as an adulterant in the illicit drug supply; limiting large-quantity retail sales is intended to reduce diversion, misuse, and associated public‑health harms.
Note: the uploaded bill files are not human‑readable in this packet. The summary below is based on the bill title, sponsors and the legislative history provided; specific statutory text (for example the exact weight threshold, enumerated exceptions, penalty structure, and enforcement mechanisms) was not available in readable form in the materials supplied.
Key provisions (as indicated by title and legislative process)
- A categorical prohibition on selling xylazine in quantities exceeding a weight threshold established in the bill (exact threshold unspecified in provided materials).
- The bill likely defines covered products and sellers (e.g., wholesalers, retailers, online vendors) and may specify permitted transactions (for example, sales to licensed veterinarians, pharmacies, or for legitimate agricultural uses). The precise exceptions and definitions are not available in the posted files.
- Enforcement and penalties: the bill presumably authorizes enforcement by state consumer protection or agriculture authorities and provides civil or criminal penalties or administrative fines for violations. Exact penalty amounts and enforcement procedures are not available in the materials provided.
Because the printed versions in the packet (1248A/1248B) are not legible here, readers should consult the official bill text to confirm definitions, thresholds, exceptions and penalty provisions.
Who would be affected
- Sellers and distributors of xylazine: veterinary suppliers, agricultural chemical dealers, online vendors and retail outlets that currently sell xylazine products.
- Licensed veterinarians and animal‑care facilities: the bill likely contains (or should contain) exemptions or special provisions for professional veterinary use; the exact scope is unknown.
- Public health and law enforcement agencies: potentially fewer large‑quantity supplies available for diversion; agencies may be charged with enforcement, monitoring and compliance.
- Consumers: agricultural and veterinary end‑users might see changes in how xylazine is packaged, sold, or documented.
Legislative progress and timeline (selected actions)
- 2025-01-09: Referred to Consumer Affairs and Protection (Assembly).
- 2025-03-25: Reported, referred to Codes.
- April–May 2025: Amendments, print number 1248A issued; reported to Ways & Means and Rules; ordered to third reading.
- 2025-05-21: Passed by the Assembly; delivered to the Senate; referred to Senate Commerce, Economic Development and Small Business.
- 2025-05-22: Amended on third reading (1248B); vote reconsidered and restored to third reading; recalled/returned to Assembly on multiple occasions.
- 2025-05-27: Repassed the Assembly and was recommitted to the Senate Consumer Protection committee (current status: RECOMMITTED TO CONSUMER PROTECTION).
Next steps / where to find full text
Because the readable bill text and the specific regulatory details (weight threshold, exceptions, penalties, enforcement authority) were not available in the files supplied here, consult the New York State Assembly or Senate legislative websites (search A.1248, printings A and B, and companion S.7668) or the Legislative Retrieval System for the enacted text and amendment language before drawing definitive conclusions about statutory requirements or compliance obligations.
